onapristone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Onapristone (INN) is a synthetic and steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and described in 1984 but was never marketed. It is a silent antagonist of the progesterone receptor (PR), in contrast to the related antiprogestogen mifepristone. Moreover, compared to mifepristone, onapristone has reduced antiglucocorticoid activity, shows little antiandrogenic activity, and has 10- to 30-fold greater potency as an antiprogestogen. The medication was under development for clinical use, for instance in the treatment of breast cancer and as an endometrial contraceptive, but was discontinued during phase III clinical trials in 1995 due to findings that liver function abnormalities developed in a majority patients.   Wikipedia

Chemistry

  • SMILES: CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24
  • InChIKey: IEXUMDBQLIVNHZ-YOUGDJEHSA-N
  • Mol. Mass: 449.64
  • ALogP: 5.16
  • ChEMBL Molecule:
    onapristone  
More Chemistry

Pharmacology

Alternative names

11 beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17 beta-(3-hydroxypropyl)-13 alpha-methyl-4,9-gonadien-3-one | estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11beta,13alpha,17alpha)- | onapristone | zk 299 | zk-299 | zk 98299 | zk 98.299 | zk-98299

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Breast Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Hamartoma (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue